Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sphygmomanometry

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7 result(s) found for: Sphygmomanometry. Displaying page 1 of 1.
    EudraCT Number: 2008-001001-41 Sponsor Protocol Number: PR002-CLN-pro008 Start Date*: 2008-06-02
    Sponsor Name:Protherics Medicines Development Ltd, a BTG plc company
    Full Title: A Randomized, Double Blind, Placebo Controlled Study of the Efficacy and Safety of Angiotensin Therapeutic Vaccine (ATV) in Patients With Mild to Moderate Hypertension
    Medical condition: Men and women, 35-70 years old with mild to moderate Hypertension as classified by the British Hypertension Society (BHS) Guidelines - BHS-IV based on the following crietia of sitting blood pressur...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    9.1 10020772 Hypertension PT
    9.1 10042957 Systolic hypertension PT
    9.1 10012758 Diastolic hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-003548-42 Sponsor Protocol Number: DAR-312-E Start Date*: 2008-04-15
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: DORADO-AC-EX – A Double-Blind, Active-Controlled, Long-Term Safety Extension Study to the Phase 3 DORADO-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension A Double-Blind, Active-...
    Medical condition: Resistant hypertension
    Disease: Version SOC Term Classification Code Term Level
    8.1 10038274 Refractory hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DK (Prematurely Ended) BE (Completed) FR (Completed) DE (Prematurely Ended) ES (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001898-25 Sponsor Protocol Number: DAR-311 Start Date*: 2006-09-21
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Effica...
    Medical condition: Resistant hypertension
    Disease: Version SOC Term Classification Code Term Level
    8.1 10038274 Refractory hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) DE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003547-23 Sponsor Protocol Number: DAR-312 Start Date*: 2007-11-15
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension A Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-center, Parallel Grou...
    Medical condition: Resistant hypertension
    Disease: Version SOC Term Classification Code Term Level
    8.1 10038274 Refractory hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) DE (Completed) BE (Completed) DK (Completed) ES (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-023612-14 Sponsor Protocol Number: N/A Start Date*: 2013-03-08
    Sponsor Name:Clinical Trials and Research Governance
    Full Title: A randomised, double-blind, placebo-controlled pilot trial of irbesartan, doxycycline and a combination on markers of vascular dysfunction in the Marfan syndrome, using cardiovascular magnetic reso...
    Medical condition: Marfan syndrome.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10026829 Marfan's syndrome PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-000771-24 Sponsor Protocol Number: CXL-1427-02 Start Date*: 2014-12-22
    Sponsor Name:Cardioxyl Pharmaceuticals, Inc.
    Full Title: A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6-Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients with Systolic Heart Failure
    Medical condition: Heart failure with reduced ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004849 10024106 Left heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001899-20 Sponsor Protocol Number: DAR-311-E Start Date*: 2007-01-16
    Sponsor Name:Gilead Sciences Inc.
    Full Title: DORADO-EX – A Dose-Blinded, Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension A Dose-Blinded, Long-Term Safety Extension Study...
    Medical condition: Resistant hypertension
    Disease: Version SOC Term Classification Code Term Level
    8.1 10038274 Refractory hypertension LLT
    Population Age: Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed) SE (Prematurely Ended) FR (Completed) DE (Prematurely Ended) IT (Prematurely Ended) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 17:03:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA